Sarcoidosis

Definition

Sarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology characterized by the formation of non-caseating granulomas (clusters of macrophages, epithelioid cells, and T lymphocytes) in affected tissues.

It most commonly affects the lungs, lymphatic system, skin, and eyes, but can involve virtually any organ, including liver, heart, kidneys, and CNS.

Pathophysiology

  • Thought to be due to an aberrant immune response to an unidentified antigen in genetically predisposed individuals.
  • CD4+ T-helper cells and macrophages accumulate in tissues → release interleukins (IL-2, IL-12, IL-18) and TNF-α → granuloma formation.
  • Non-caseating granulomas distinguish sarcoidosis from infections (e.g., tuberculosis) which form caseating granulomas.
  • Chronic inflammation can cause fibrosis and organ dysfunction.

Epidemiology

  • Peak incidence: 20–40 years old.
  • Slight female predominance.
  • More common in African and Scandinavian populations.
  • May mimic metastatic disease on imaging, hence relevance in oncology practice.

Common Sites of Involvement

System Key Manifestations Notes for Oncology Pharmacist
Lungs / Mediastinal Lymph Nodes Dry cough, dyspnea, bilateral hilar lymphadenopathy Can mimic metastatic or lymphomatous lesions on CT or PET; biopsy required
Skin Erythema nodosum, lupus pernio Cutaneous lesions may need topical/systemic corticosteroids
Eyes Uveitis, conjunctivitis May lead to blindness if untreated
Liver / Spleen Granulomatous hepatitis, hepatomegaly Monitor liver function in patients on systemic therapy
Heart Arrhythmias, cardiomyopathy Avoid QT-prolonging drugs; monitor EKG
CNS Cranial nerve palsy, meningitis High-dose corticosteroids often required

Diagnosis

  • Histologic confirmation of non-caseating granulomas (via biopsy).
  • Exclusion of other granulomatous diseases (TB, fungal infection, lymphoma).
  • Supportive tests:
    • ↑ ACE (angiotensin-converting enzyme) levels (nonspecific).
    • ↑ Calcium (hypercalcemia due to 1α-hydroxylase activity in macrophages).
    • Chest X-ray/CT: bilateral hilar lymphadenopathy, pulmonary infiltrates.
    • PET-CT may show FDG-avid lesions (can resemble metastases).

Staging (Pulmonary Sarcoidosis)

Stage Radiographic Finding Prognosis
0 Normal chest X-ray Best
I Bilateral hilar adenopathy Often self-limited
II Adenopathy + pulmonary infiltrates Intermediate
III Pulmonary infiltrates only Risk of fibrosis
IV Pulmonary fibrosis Chronic, irreversible

Pharmacologic Management

Drug Class Example Role / Mechanism Clinical Notes (for Pharmacists)
Corticosteroids Prednisone First-line; suppresses granulomatous inflammation Start ~20–40 mg/day, taper over 6–12 months; monitor glucose, BP, bone health
Steroid-sparing immunosuppressants Methotrexate, Azathioprine, Leflunomide Reduce steroid exposure; useful in chronic or refractory disease MTX: weekly dosing (10–25 mg/week) with folic acid; monitor LFTs and renal function
Antimalarials Hydroxychloroquine Especially for skin or hypercalcemia Ophthalmic exams required
Biologic agents (anti-TNF) Infliximab, Adalimumab For refractory pulmonary, cutaneous, or neurosarcoidosis Screen for TB/hepatitis; monitor infection risk; avoid in malignancy history unless risk-benefit justified
Other agents (refractory cases) Mycophenolate mofetil, Cyclophosphamide Last-line; multidisciplinary oversight Cyclophosphamide may be used in severe neurosarcoidosis—oncology pharmacists should monitor cytopenias and bladder toxicity

Oncology Pharmacist’s Perspective

Aspect Key Relevance
Differential diagnosis Sarcoidosis can mimic lymphoma or metastatic disease (PET-avid lymph nodes, pulmonary nodules). Tissue biopsy is crucial before labeling recurrence.
Drug interactions Corticosteroids and immunosuppressants interact with oncology drugs (e.g., increased infection risk with chemo, additive hepatotoxicity with MTX).
Biologic overlap Anti-TNF biologics used in sarcoidosis (e.g., infliximab) are also used in oncology-related immune complications (e.g., immune checkpoint inhibitor–induced pneumonitis).
Monitoring Monitor CBC, LFTs, renal, glucose, calcium, and infectious markers; watch for steroid-induced myopathy or osteoporosis.
Special cases Sarcoidosis may occur after immune checkpoint inhibitor therapy (sarcoid-like reaction), requiring differentiation from tumor progression.

Drug Treatment

Drug (typical sarcoidosis dose — adult)

Mechanism (concise)

Monitoring (baseline & ongoing)

Major toxicities / ADRs

Oncology-relevant comments

Prednisone / Prednisolone (Initial 20–40 mg/day; severe organ disease 0.5–1 mg/kg/day; taper to lowest effective dose; total duration months–years)

Broad anti-inflammatory & immunosuppressive glucocorticoid

BP, glucose, weight, electrolytes, bone density (DEXA q1–2 yr), ophthalmic exam if long term, infection surveillance

Hyperglycemia, HTN, osteoporosis, myopathy, psychosis, immunosuppression/infection risk, peptic ulcer

Widely used to treat ICI-related sarcoid-like reactions and sarcoidosis. Steroids blunt vaccine responses and increase infection risk with chemotherapy—coordinate timing. Consider PJP prophylaxis when combined with other immunosuppressants.

Methotrexate (MTX) (7.5–25 mg PO/SC once weekly, commonly 10–15 mg/wk) + folic acid 1 mg/day

Antimetabolite inhibiting dihydrofolate reductase; immunomodulatory (reduces granuloma formation)

CBC, LFTs, creatinine at baseline and q4–8 weeks initially; monitor for pulmonary toxicity; pregnancy test in WOCBP

Hepatotoxicity, cytopenias, stomatitis, mucositis, pneumonitis, teratogenicity

MTX causes additive myelosuppression/cytopenias with cytotoxic chemo — avoid concurrent use with many chemo regimens. Hepatotoxicity may confound interpretation of chemo liver injury. Teratogen — strict contraception. Folate reduces mucosal toxicity.

Azathioprine (AZA) (1–3 mg/kg/day PO)

Purine synthesis inhibitor → reduced lymphocyte proliferation

TPMT or NUDT15 genotyping/phenotyping before start (if available); CBC and LFTs baseline and q2–4 weeks initially

Myelosuppression, hepatotoxicity, increased infection risk, pancreatitis

Myelosuppression may complicate cytotoxic chemo; interaction with allopurinol (requires AZA dose reduction). Malignancy risk (lymphoproliferative) reported with long-term use; discuss with oncology.

Mycophenolate mofetil (MMF) (500–1500 mg PO BID; total 1–3 g/day)

Inhibits inosine monophosphate dehydrogenase → inhibits lymphocyte proliferation

CBC, LFTs, renal function q4–8 weeks; drug levels not routinely used

GI upset, leukopenia, infections, teratogenicity

Potent immunosuppressant — increased infection risk during chemo or biologic therapy. Avoid live vaccines.

Leflunomide (loading 100 mg/day x3 days then 10–20 mg/day)

Inhibits pyrimidine synthesis → anti-proliferative effect on lymphocytes

LFTs baseline and q1–2 months; monitor BP; pregnancy test & cholestyramine washout for pregnancy planning

Hepatotoxicity, hypertension, teratogenicity, cytopenias

Teratogenic — strict pregnancy avoidance and cholestyramine washout if pregnancy planned. Hepatotoxicity overlaps with chemo hepatotoxicity.

Hydroxychloroquine (HCQ) (200–400 mg/day PO)

Antimalarial; immunomodulatory (inhibits antigen presentation, reduces macrophage activity)

Baseline ophthalmologic exam (visual acuity, visual fields, OCT); annual eye exams after 5 yrs (earlier if high dose) ; CBC, LFTs

Retinopathy (dose & duration dependent), GI upset, skin reactions

Useful for cutaneous sarcoidosis & hypercalcemia. Minimal myelosuppression — often safe with many oncology regimens but monitor for interactions and cumulative immunosuppression.

Cyclophosphamide (IV pulse) (500–1000 mg/m² IV q3–4 weeks, or tailored pulse regimens)

Alkylating agent → profound immunosuppression; used in severe/refractory neurosarcoid or cardiac sarcoid

CBC, renal & hepatic function, urinalysis (hemorrhagic cystitis), pregnancy test, cumulative dose tracking

Myelosuppression, hemorrhagic cystitis, gonadotoxicity, secondary malignancy risk (bladder, hematologic)

This is a cytotoxic chemo agent — clear overlap with oncology practice. Manage like chemo: hydration, MESNA if high dose, fertility counseling, VTE risk, infection risk.

Infliximab (5 mg/kg IV at 0,2,6 weeks then q4–8 weeks; dosing individualized)

Chimeric anti-TNF-α monoclonal antibody — reduces granuloma maintenance

TB screening (IGRA/PPD + CXR) and hepatitis B/C screening pre-treatment; CBC, LFTs; monitor for infections

Infusion reactions, increased risk of serious infections (TB reactivation), hypersensitivity, possible increased malignancy risk in some populations

Anti-TNF agents substantially increase risk of latent TB reactivation — mandatory screening and treatment if needed. Concomitant chemo increases infection risk; anti-TNFs may blunt efficacy of cancer immunotherapy (complex interplay). Avoid live vaccines during therapy.

Adalimumab (40 mg SC q1–2 weeks, often 40 mg q2w)

Fully human anti-TNF-α monoclonal antibody

Same as infliximab: TB/hep B/C screening before start; CBC, LFTs; monitor infections

Injection site reactions, infections, rare demyelination, possible malignancy signal

Same anti-TNF precautions. Subcutaneous administration easier outpatient. Important interplay with immunotherapy — may be used to treat steroid-refractory ICI toxicities but may blunt anti-tumor immunity.

Rituximab (375 mg/m² IV weekly x4 or 1 g IV x2 two weeks apart)

Anti-CD20 B-cell depleting antibody — used for refractory neurosarcoid / severe disease

Hepatitis B screening (HBsAg, anti-HBc); CBC, immunoglobulins; monitor for infusion reactions and late hypogammaglobulinemia

Infusion reactions, prolonged B-cell depletion → hypogammaglobulinemia, infections, HBV reactivation

Rituximab is widely used in oncology; oncology pharmacists should apply same HBV reactivation prophylaxis protocols. May impair vaccine responses for months.

Other biologics (e.g., ustekinumab, tocilizumab) (used off-label in refractory cases)

Targeted cytokine blockade (IL-12/23, IL-6)

Screening for infection/hepatitis/TB per agent; specialized labs

Infection risk, lab-specific toxicities (e.g., transaminitis)

Off-label; consult multidisciplinary team. Potential interactions with chemotherapy; limited evidence in sarcoid.

Topical / inhaled corticosteroids (e.g., inhaled fluticasone for airway disease; topical steroids for skin lesions)

Local anti-inflammatory effects

If high-dose inhaled: adrenal suppression, oral candidiasis; topical: skin atrophy

Local ADRs, systemic absorption with high doses

Often preferred for isolated airway/skin disease to minimize systemic immunosuppression that can complicate cancer therapy.

Supportive / prophylactic considerations (not a drug)

—

Vaccination status review: avoid live vaccines on immunosuppression; consider inactivated vaccines pre-treatment when possible

—

Coordinate vaccine timing with oncology/chemo schedules; live vaccines contraindicated while on biologics/immunosuppressants. Consider PJP prophylaxis (TMP-SMX) if prolonged high-dose steroids + another immunosuppressant.

Practical management points for the oncology pharmacist

  1. Differentiate sarcoidosis from malignancy.
    • Sarcoid granulomas and sarcoid-like reactions (including ICI-related) can be FDG-avid on PET and mimic metastases or lymphoma. Emphasize tissue biopsy when imaging is ambiguous — avoid reflex systemic therapy for presumed progression without histology.
  2. Baseline infection screening is mandatory before biologics/rituximab/cyclophosphamide.
    • TB: IGRA or PPD + chest imaging.
    • Viral hepatitis: Hep B (HBsAg, anti-HBc) and Hep C.
    • Manage latent infections before starting anti-TNF or B-cell depleting therapy.
  3. Vaccinations & live vaccines.
    • Administer needed inactivated vaccines before initiating immunosuppression when possible. Live vaccines are contraindicated during immunosuppression and for variable time after (agent-dependent).
  4. Drug–drug interactions & overlapping toxicities with oncology therapies.
    • MTX, AZA, MMF → additive myelosuppression with cytotoxic agents. Adjust dosing or sequence therapy carefully.
    • Hepatotoxic agents (MTX, leflunomide, azathioprine) may worsen chemo-related liver injury. Monitor LFTs closely.
    • Anti-TNF and rituximab: markedly increase infection risk when combined with cytotoxic chemo or high-dose steroids. Rituximab impairs humoral response to vaccines and can increase HBV reactivation risk; follow oncology prophylaxis protocols.
  5. Steroids and cancer treatment.
    • Steroids are often needed (e.g., for neurosarcoidosis or severe organ involvement) but may interfere with immune checkpoint inhibitor (ICI) therapies and increase infection risk. If sarcoid is ICI-related, coordinate with the oncology team — sometimes localized therapy or steroid-sparing agents are preferred.
  6. Infection prophylaxis.
    • Consider Pneumocystis jirovecii prophylaxis (e.g., TMP-SMX) for patients on prolonged high-dose steroids plus another immunosuppressant. Follow institutional thresholds.
  7. Fertility / pregnancy concerns.
    • MTX, leflunomide, cyclophosphamide are teratogenic — counsel patients on contraception and fertility preservation where appropriate.
  8. When oncology treatments are ongoing (chemo / targeted therapy / immunotherapy):
    • Collaborate with oncology and the sarcoidosis subspecialty to sequence therapies safely. Sometimes sarcoidosis treatment must be modified (dose reductions, alternative agents, or temporary holds) to permit essential cancer therapy.

Quick reference — screening/action checklist before starting steroid-sparing agents or biologics

  • CBC, CMP (renal/hepatic), baseline chest X-ray/CT if not done, pregnancy test if applicable.
  • TB screen (IGRA/Purified Protein Derivative) + CXR — mandatory before anti-TNF.
  • HBsAg and anti-HBc (hepatitis B) and HCV testing.
  • TPMT/NUDT15 testing for azathioprine if available.
  • Ophthalmology baseline for HCQ if long-term use planned.
  • Vaccination review; administer inactivated vaccines pre-treatment when possible.

Summary

  • Sarcoidosis = systemic non-caseating granulomatous disorder, commonly involving the lungs.
  • May mimic malignancy radiographically; tissue confirmation essential.
  • Corticosteroids are first-line; methotrexate or biologics for steroid-refractory disease.
  • Oncology pharmacists play a key role in drug selection, monitoring toxicity, managing drug–disease and drug–drug interactions, and distinguishing disease vs treatment-related effects.
Tags: